A CRISPR Way
The US Food and Drug Administration has issued an Emergency Use Authorization for a CRISPR-based test for SARS-CoV-2, as GenomeWeb reports.
The test from Sherlock Biosciences relies on its Specific High-sensitivity Enzymatic Reporter unLOCKing platform, known as SHERLOCK. According to the firm, the platform works by programming CRISPR to detect a particular genetic signature, which, when found, leads the CRISPR enzyme to generate a signal the system then detects. For its new test kit, it recognizes a genetic signature from SARS-CoV-2 from nasal, nasopharyngeal, or oropharyngeal swab samples or from a bronchoalveolar lavage specimen.
As the Verge notes, this is the first time FDA has authorized a CRISPR-based tool, and it notes that the tool may enable rapid testing. GenomeWeb adds that the Sherlock CRISPR SARS-CoV-2 kit is supposed to provide results in about an hour.
Ubigene Biosciences is co-founded by biological academics and elites from China, the United States, and France. We are located in Guangzhou Science City, which serves as a global center for high technology and innovation. Ubigene Biosciences has 1000㎡ office areas and laboratories, involving genome editing, cell biology technology, and zebrafish research. We provide products and services for plasmids, viruses, cells, and zebrafish. We aim to provide customers with better gene-editing tools for cell or animal research.
We developed CRISPR-U™ and CRISPR-B™(based on CRISPR/Cas9 technology) which is more efficient than general CRISPR/Cas9 in double-strand breaking, CRISPR-U™ and CRISPR-B™ can greatly improve the efficiency of homologous recombination, easily achieve knockout (KO), point mutation (PM) and knockin (KI) in vitro and in vivo.
Genome Editing Platform
——Focusing on the Application of CRISPR-U™ and CRISPR-B™ Gene Editing Technology
Cell Biology Platform
——Focusing on primary cell
2. Provides culture strategies and related products for different cell types.3. Provides cell biology-related services such as cell isolation, extraction and validation.